Phathom Pharmaceuticals, Inc. beat EPS estimates 88% of the time across 16 reported quarters (14 beats, 2 misses), averaging +13.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.15 | $-0.08 | +46.7% | Beat | Q2 FY26 call |
| Q1 FY26 | $-0.27 | $-0.25 | +7.4% | Beat | |
| Q4 FY25 | $-0.20 | $-0.16 | +20.0% | Beat | Q4 FY25 call |
| Q3 FY25 | $-0.40 | $-0.28 | +30.0% | Beat | |
| Q2 FY25 | $-0.86 | $-0.90 | -4.7% | Miss | |
| Q1 FY25 | $-1.16 | $-1.15 | +0.9% | Beat | |
| Q4 FY24 | $-1.08 | $-0.88 | +18.5% | Beat | |
| Q3 FY24 | $-1.57 | $-1.32 | +15.9% | Beat | |
| Q2 FY24 | $-1.39 | $-1.35 | +2.9% | Beat | |
| Q1 FY24 | $-1.43 | $-1.42 | +0.7% | Beat | |
| Q4 FY23 | $-0.92 | $-0.80 | +13.0% | Beat | |
| Q3 FY23 | $-0.95 | $-0.76 | +20.0% | Beat |
Back to PHAT overview · PHAT holders · PHAT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.